Return
Long-Term Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment: Results From the LUCENT-3 Open-Label Extension Study
S
D
C
I
J
G
A
L
H
K
D
S
S
P
M
M
A
D
P
DOI:.png)
Abstract
En
Journal
IF:
7.6
Papers:
5.1W
Citations:
3.3W
